America Cancer Immunotherapy Market Size (2024 - 2029)

The Americas Cancer Immunotherapy Market is poised for substantial growth, driven by the increasing prevalence of cancer and the rising effectiveness of innovative therapies. The market's expansion is supported by enhanced research and development activities, strategic initiatives, and increased funding within the industry. The demand for advanced cancer treatments, such as immunotherapy, is expected to rise due to the growing cancer burden in the region. Additionally, supportive government legislation and regulatory approvals are anticipated to further accelerate market growth, as seen with recent FDA approvals for new immunotherapy combinations and treatments.

Market Size of America Cancer Immunotherapy Industry

America Cancer Immunotherapy Market Summary
Study Period 2024 - 2029
Market Size (2024) USD 70.12 Billion
Market Size (2029) USD 96.17 Billion
CAGR (2024 - 2029) 8.76 %
Fastest Growing Market South America
Largest Market North America
Market Concentration Low

Major Players

America Cancer Immunotherapy Market Major Players

*Disclaimer: Major Players sorted in no particular order

America Cancer Immunotherapy Market Analysis

The Americas Cancer Immunotherapy Market size is estimated at USD 70.12 billion in 2024, and is expected to reach USD 96.17 billion by 2029, growing at a CAGR of 8.76% during the forecast period (2024-2029).

The American cancer immunotherapy market is anticipated to witness significant growth opportunities due to the rising burden of cancer, rising R&D activities, and the increasing effectiveness and accuracy of newer therapies. In addition, growing funding activities and several strategic initiatives undertaken by industry participants are projected to accelerate market growth over the study period.

The alarming increase in the burden of cancer across the Americas is expected to bolster the demand for innovative cancer therapies like immunotherapy to treat the condition. For instance, according to the American Cancer Society, the estimated number of new cancer cases ramped up from 1.9 million in 2023 to 2.0 million in 2024. The most common type of cancers diagnosed in 2023 were breast, lung, and hematological malignancies.

Similarly, according to the estimates from the National Cancer Institute of Brazil, around 704 thousand new cancer cases are expected to be diagnosed between 2023 and 2025, except non-melanoma skin cancer. Thus, such an alarming burden of cancer in the region is projected to accelerate the uptake of novel cancer therapies like immunotherapy for the effective treatment of disease.

Thus, the increased burden of cancers has accelerated the adoption of advanced cancer treatment options like immunotherapies. Moreover, several clinical benefits of immunotherapies in cancer and leveraging the role of immunotherapies in cancer management are further expected to accelerate market growth over the study period.

For instance, according to an article published by the International Journal of Molecular Sciences in September 2023, immunotherapy recently emerged as an innovative treatment option for lethal cancers like prostate cancer. It has several clinical benefits, including targeted therapy and improved clinical outcomes. Thus, leveraging the role of immunotherapy in the management of cancers is expected to accelerate market expansion over the study period.

Furthermore, supportive government legislation and growing regulatory approvals are further projected to accelerate industry expansion over the study period. For instance, in March 2024, the United States Food and Drugs Administration (U.S.FDA) approved Bristol Myers Squibb’s Opdivo (nivolumab) in combination with gemcitabine and cisplatin for the first-line treatment of metastatic urothelial carcinoma in adults. This approval marked one of the key immunotherapy-chemotherapy combinations approved for patients with metastatic urothelial carcinoma.

Similarly, in July 2022, the US FDA accepted Genentech’s Biologics License Application (BLA) and granted Priority Review for mosunetuzumab, a T-cell-engaging bispecific antibody. The immunotherapy drug is a first-in-class CD20xCD3 T-cell-engaging bispecific antibody intended for the management of relapsed or refractory (R/R) follicular lymphoma (FL) in adult patients. Thus, such growing regulatory approvals are projected to foster market growth over the study period.

Moreover, in March 2024, Caring Cross and Fundação Oswaldo Cruz collaborated to develop domestic production of stem cell gene therapies and CAR-T cell therapies for various types of cancers, including leukemia, and lymphoma.

America Cancer Immunotherapy Industry Segmentation

As per the scope of the report, immunotherapy is a treatment that uses certain parts of a person’s immune system to fight diseases, such as cancer. This can be done by stimulating one’s immune system to work better to attack cancer cells or by giving one immune system components, such as artificial immune system proteins. America's cancer immunotherapy market is segmented by therapy type, application, end-user, and geography. Based on therapy type, the market is segmented into monoclonal antibodies, cancer vaccines, immunomodulators, immune checkpoint inhibitors, and other therapy types. Based on application, the market is segmented into prostate cancer, breast cancer, skin cancer, lung cancer, and other applications. Based on end users, the market is segmented into hospitals and clinics, cancer research centers, and other end users. The report also covers the market sizes and forecasts for the Americas Cancer Immunotherapy market in major countries across different regions. The market size is provided for each segment in terms of value (USD).

By Therapy Type
Monoclonal Antibodies
Cancer Vaccines
Immunomodulators
Immune Check Point Inhibitors
Other Therapy Types
By Application
Prostate Cancer
Breast Cancer
Skin Cancer
Lung Cancer
Other Applications
By End Users
Hospitals and Clinics
Cancer Research Centers
Other End Users
Geography
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

America Cancer Immunotherapy Market Size Summary

The Americas cancer immunotherapy market is poised for substantial growth, driven by the increasing prevalence of cancer and the rising demand for innovative treatment options. The market is characterized by a surge in research and development activities, alongside significant funding and strategic initiatives by industry players. These factors are expected to enhance the effectiveness and accuracy of newer therapies, thereby accelerating market expansion. The growing burden of cancer, particularly in the United States and Brazil, is propelling the adoption of immunotherapy as a viable treatment option. This trend is further supported by supportive government legislation and regulatory approvals, which are facilitating the introduction of novel therapies into the market.

North America is anticipated to experience significant growth due to its advanced medical infrastructure and robust healthcare research environment. The region's market expansion is fueled by the increasing number of cancer cases, which elevates the demand for immunotherapy. Recent developments in research, such as the creation of advanced nanoparticles for enhanced drug delivery, and strategic initiatives by market players are contributing to this growth. The market is fragmented, with several key players like Amgen Inc., Bayer AG, and Bristol-Myers Squibb actively investing in research and product development to strengthen their market positions. These dynamics, coupled with the rising burden of cancer and ongoing regulatory support, are expected to drive the Americas cancer immunotherapy market forward over the forecast period.

Explore More

America Cancer Immunotherapy Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising R&D Activities and Increasing Effectivity and Accuracy Of Newer Therapies

      2. 1.2.2 High Burden of Cancer

    3. 1.3 Market Restraints

      1. 1.3.1 Side Effects Associated With the Immunotherapy

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market size by Value in USD)

    1. 2.1 By Therapy Type

      1. 2.1.1 Monoclonal Antibodies

      2. 2.1.2 Cancer Vaccines

      3. 2.1.3 Immunomodulators

      4. 2.1.4 Immune Check Point Inhibitors

      5. 2.1.5 Other Therapy Types

    2. 2.2 By Application

      1. 2.2.1 Prostate Cancer

      2. 2.2.2 Breast Cancer

      3. 2.2.3 Skin Cancer

      4. 2.2.4 Lung Cancer

      5. 2.2.5 Other Applications

    3. 2.3 By End Users

      1. 2.3.1 Hospitals and Clinics

      2. 2.3.2 Cancer Research Centers

      3. 2.3.3 Other End Users

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 South America

        1. 2.4.2.1 Brazil

        2. 2.4.2.2 Argentina

        3. 2.4.2.3 Rest of South America

America Cancer Immunotherapy Market Size FAQs

The America Cancer Immunotherapy Market size is expected to reach USD 70.12 billion in 2024 and grow at a CAGR of 8.76% to reach USD 96.17 billion by 2029.

In 2024, the America Cancer Immunotherapy Market size is expected to reach USD 70.12 billion.

America Cancer Immunotherapy Market - Growth, Trends, and Forecasts (2024- 2029)